Loading…

Abbott LaboratoriesABTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Diversified healthcare company making medical devices (diabetes care, cardiovascular), diagnostics, nutrition products and generic pharmaceuticals.

Momentum strong 66
Mkt cap
$181B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$898M
20-day average traded
Fwd P/E
17.9×
forward earnings
ROIC−WACC
-0.6 pp
WACC 7.4%
Hurdle
+11 pp
Req g minus delivered
Official | Implied
A+ / AA-
agencies · bond market
Next earnings
70 days
27 Jan 2027
Close · USD$104.48
1D-0.2%
1W-4.4%
1M+2.0%
3M-8.5%
6M+18.2%
YTD-15.7%
1Y-18.7%
ATR %2.9%
Beta0.10
52w lowhigh20.0% off high

What Abbott Laboratories does

Diversified healthcare company making medical devices (diabetes care, cardiovascular), diagnostics, nutrition products and generic pharmaceuticals.

Sells through hospitals, pharmacies and retail shelves: glucose sensors replaced every few weeks, diagnostics instruments with tests, heart and brain devices, and nutrition products. The sensors recur, which makes FreeStyle Libre a repeat-purchase growth line beside the one-off device sales.

Products and services

  • Diabetes Care (FreeStyle Libre CGM)
  • Diagnostics
  • Medical Devices (cardiovascular, neuromodulation)
  • Nutrition (Ensure, Similac)

Customers

  • Hospitals/physicians
  • People with diabetes/consumers
  • Infant/adult nutrition consumers
  • Emerging-market pharmacies

Where it sits in the supply chain

  • Healthcare
  • Diversified…
  • Devices + diagnostics + nutrition +…

What could go right

  • FreeStyle Libre CGM volume growth
  • Emerging-market nutrition/diagnostics demand

What could go wrong

  • Infant-formula recall/regulatory risk
  • Pricing pressure in diagnostics/generics

Moat: wide (brand, installed base, scale). Leading positions across CGM, diagnostics and infant nutrition with strong brand loyalty and device ecosystems.

Headquarters: Abbott Park, Illinois, USA · Founded: 1888 · Employees: 115,000

Named competitors

Abbott Laboratories at a glance

Size Abbott Laboratories (ABT) is a United States Health Care company (Medical Specialties) with a market value of $181B, the 67th largest of 3,085 United States companies the cockpit tracks. Shares closed at $104.48 on 18 Nov 2026.

Performance Over six months the shares gained 18.2%, against +26.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 16 in its peer set.

Growth Revenue grew 10.0% over the last twelve months (peer median +8.9%); the operating margin is 14.2% (peer median 20.9%).

Valuation It trades at 17.9× forward earnings against a peer median of 25.6× (4th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.6 points below its cost of capital (7.4% WACC).

Credit Abbott Laboratories has 17 bonds outstanding ($30.3B), rated A+ by the agencies and trading like AA- at a weighted spread of 67 bp.

Short interest Short interest is 1.1% of the free float (30 Oct 2026).

Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 126ABT 119
Six months, rebased to 100: Abbott Laboratories against the median of its 15 peers (local-currency closes).

Abbott Laboratories financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$48.2B$44.3B$42.0B$40.1B$43.7B
Revenue growth—+6%+5%-8%—
Gross profit$25.2B$23.4B$21.3B$20.0B$22.3B
EBITDA$10.8B$11.4B$10.1B$9.68B$11.6B
Net income$4.72B$6.50B$13.4B$5.70B$6.91B
Free cash flow$6.76B$7.39B$6.35B$5.06B$7.80B
Capital expenditure$2.10B$2.17B$2.21B$2.20B$1.78B
Total debt$31.2B$14.1B$15.3B$15.9B$17.9B

Quarterly statements and history in the cockpit →

Abbott Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%DHRISRGMDTTMOSYKELBSXEWBDXIDXXMDLNA7741ABT6-month return →1-month return →
Up and to the right = strong over both horizons. Abbott Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×30×40×DHRISRGMDTTMOSYKBSXEWBDXIDXXAWATABTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Abbott Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%DHRISRGMDTTMOSYKELBSXEWBDXIDXXSHLAWATABTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Abbott Laboratories is the large dot.

Abbott Laboratories competitors and peer comparison

Head to head with its named competitors (ABT vs MDT vs DXCM vs DHR)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Dexcom DXCM$30.8B+16%+13%24%28.0×19.6%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Nestle NESN.SW$258B+8%-2%16%19.1×1.3%

How Abbott Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Abbott Laboratories against its 15 peers (data as of 18 Nov 2026)
MeasureABTPeer medianRank in peer set
1-month return+2.0%+5.2%6th lowest of 16
6-month return+18.2%+26.6%7th lowest of 16
Distance from 52-week high-20.0%-7.2%6th lowest of 16
Revenue growth (TTM)+10.0%+8.9%7th highest of 16
Operating margin14.2%20.9%5th lowest of 16
Forward P/E17.9×25.6×4th cheapest of 16
Growth the price implies (Req g, 7 yrs)16.5%17.1%8th least demanding of 16
Growth delivered (Del g)+5.1%+6.7%4th lowest of 16
Hurdle (Req g minus delivered)+11.4 pp+6.0 pp6th most demanding of 16
ROIC minus cost of capital-0.6 pp+1.9 pp6th lowest of 16
EV / EBITDA19.3×22.6×8th cheapest of 16
Net debt / EBITDA2.5×1.9×6th most indebted of 16
Bond spread67 bp74 bp3rd tightest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Abbott Laboratories ABTUnited States$181B+18%+10%14%17.9×16.5%+5.1%
Danaher DHRUnited States$161B+34%+6%21%25.1×20.8%+2.0%
Intuitive Surgical ISRGUnited States$146B-6%+20%32%34.8×29.6%+18.2%
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Thermo Fisher Scientific TMOUnited States$257B+53%+8%19%25.7×21.3%+6.7%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%

Abbott Laboratories bonds and credit

Abbott Laboratories has 17 bonds outstanding with $30.3B face value. The agencies rate it A+; its bonds trade like AA-. Weighted yield 5.60%, a spread of 67 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Abbott Laboratories's main competitors?
Named competitors: Medtronic (MDT), Dexcom (DXCM), Danaher Corporation (DHR), Nestle (NESN.SW). The cockpit's measured peer set (industry) also includes Danaher (DHR), Intuitive Surgical (ISRG), Medtronic (MDT), Thermo Fisher Scientific (TMO), Stryker (SYK), EssilorLuxottica (EL.PA).
Is Abbott Laboratories expensive compared with its peers?
On forward p/e it trades at 17.9× against a peer median of 25.6×, 4th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Abbott Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +18.2% against +26.6% for the median peer; over one year -18.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.